Speir, Mary
Hermans, Ian F.
Weinkove, Robert
Funding for this research was provided by:
Genesis Oncology Trust (GOT-1352-RPG)
Article History
First Online: 22 December 2016
Compliance with Ethical Standards
:
: The writing of this manuscript was supported by Genesis Oncology Trust (NZ) (grant number GOT-1352-RPG to RW).
: IH: Proprietary interest and member of management team of Avalia Immunotherapies. RW: Scientific Advisory Board member for Avalia Immunotherapies; part-time employee of the Malaghan Institute of Medical Research, which has an interest in Avalia Immunotherapies. MS: Employed by the Malaghan Institute of Medical Research, which has an interest in Avalia Immunotherapies.
Free to read: This content has been made available to all.